The indication is for patients with inherited BRCA-mutated locally advanced or metatastatic breast cancer.
News
MHRA renews EAMS scientific opinion for Puldysa in DMD
The drug has been available in the UK through EAMS since June 2017.
Boosting natural repair could help solve age related macular degeneration
Fight for Sight has announced funding for scientists at Queen’s University Belfast.
£8m drug-resistance grant for Oxford Drug Design
Drug-resistant superbugs are on the rise worldwide and represent a threat to global public health and health security.
NHS rolls-out stroke teams across UK
A new study has found that 170 extra lives are saved a year in London and Manchester alone.
1/3 of Brits stockpile medication
Painkillers, cold and flu remedies and antiseptic were amongst those most likely to be kept past their expiry date.
EU approval for Novo’s Esperoct
The decision follows the positive opinion from the CHMP.
NHS to fast-track ‘game changing’ cancer drugs
The revolutionary treatments can be used against a wide range of cancers.
4 pharma companies accused of anti-competitive conduct
The CMA has accused Alissa, Lexon, King and Auden Mckenzie of engaging in anti-competitive conduct.
New implant recommended by NICE for uveitis
The fluocinolone acetonide implant could mean fewer hospital visits for patients who receive the current treatments.
Medicines Discovery Catapult, MQ, Alzheimer’s Research UK form alliance
The partnership will focus on identifying and validating novel drug targets for unmet therapeutic needs for psychiatric symptoms affecting people with mental health conditions
Pfizer to invest £5M in paediatric medicines
The news coincides with the Medicines Manufacturing Industry Partnership (MMIP) annual conference.
Lynparza bags EU approval for RCA-mutated advanced ovarian cancer
The approval was based on data from the pivotal Phase III SOLO-1 trial.
Millions in UK living with undiagnosed COPD
Breathlessness affects 10% of the UK population and up to 30% of older people.
Boehringer, Uni of Dundee extend anti-cancer alliance
The collaboration will continue to develop new medicines that target and destroy key cancer causing proteins.
